Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Full Disclosure Trading -- Ignore unavailable to you. Want to Upgrade?

To: Return to Sender who wrote (6564)	7/31/2003 12:21:18 PM
From: ALTERN8	Read Replies (1) \| Respond to of 13403

BRCM bot 1700 @ 20.18

To: Return to Sender who wrote (6564)	7/31/2003 12:29:36 PM
From: seminole	Read Replies (1) \| Respond to of 13403

OT; <<< How far do you let a winner like MOGN run before taking profits? >>> The rule of thumb I use for drug approval is one half of the stock move comes before approval ($8 to $28) and one half comes after approval ($28 to $48). I would let it run as long as the volume is increasing and as the institutional money comes to MOGN. (% institution ownership can be found at NASDAQ site) I would let it run through the first quarter of Aloxi sales because the doubling of company revenues will put it on a lot of buy list. My ownership; I posted it here as a Buy at $6-7. I bought for my IRAs at $3-5, and converted to a Roth at $6. I bought for my regular and trading account at $3-10. I have a large core postion and my trading shares I have kept since January without a sale.